Gilead Acquires Tubulis to Boost Oncology Pipeline
FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026 Gilead Sciences, Inc. announced a definitive agreement to...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026 Gilead Sciences, Inc. announced a definitive agreement to...
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
